All ten analysts who have coverage on Piramal Pharma have a “buy” recommendation on the stock. Previous Post IKS Health IPO share allotment today as GMP crosses ₹400: Steps to check status on NSE, BSE and Link Intime Next Post Marketbuzz Podcast with Kanishka Sarkar: Market likely to open with cuts, Vedanta, Varun Beverages in focus Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Post Comment
